AMICULUM has significant experience working with clients and stakeholders involved in the development of new treatments for rare diseases and uncommon cancers.

Our agencies have provided support for the development and promotion of access to effective treatments for rare diseases and uncommon cancers for over 10 years.  AMICULUM recently established Comradis, an agency which will work exclusively in this sector.

Comradis has three key areas of expertise:

COMMUNICATIONS: we work with pharmaceutical industry clients and other stakeholder groups on the development of healthcare communications and learning programmes designed to raise awareness of, and improve access to, treatments for rare diseases.  Comradis works though all communication channels including publications, meetings and digital engagement, including e-learning and social media initiatives.  Like other AMICULUM teams, Comradis has the skills required to devise and implement effective and tailored communication strategies.

COMMUNITIES: our teams have established close partnerships with healthcare professionals in the creation and delivery of medical education projects.  Our focus on new drugs for use in areas of high unmet medical need means that we have gained experience working with many rare disease specialists.  We are now facilitating collaboration with other rare disease stakeholders such as patient advocacy groups and enjoy the interaction with these highly motivated and well-informed partners.  Our significant digital experience allows us to connect communities of professionals and other stakeholders using the latest interactive technologies.

COMMERCIALIZATION: Comradis is able to provide support to pharmaceutical industry clients to facilitate successful commercialization of new treatments for rare diseases. We have helped our clients to devise launch plans, and forecasts for conditions and markets where there are only sparse data, and provided ad hoc support to brand teams with limited internal resource.

Our teams have consistently demonstrated the ability to get ‘up to speed’ in new and demanding therapy areas and our work in rare diseases is no exception.  To date we have worked in neuroendocine tumours, medullary thyroid cancer, pulmonary hypertension, lysosomal storage disorders and rare inherited anaemias.